Dr. Daniel Stone speaks with Drs. Mario Mietzsch and Robert McKenna from the University of Florida to discuss a recent article published in the Biomanufacturing in Gene and Cell Therapy special issue of Molecular Therapy Methods & Clinical Development by Drs. Mietzsch, McKenna, and colleagues titled Production and characterization of an AAV1-VP3-only capsid: An analytical benchmark standard.

If you enjoy today’s conversation, you’ll also enjoy the upcoming ASGCT Policy Summit in Washington, DC, September 23-24. 

This can't-miss event brings together policymakers and gene and cell therapy experts, including FDA leaders Julie Tierney and Dr. Nicole Verdun, to discuss the latest policies impacting this rapidly evolving field. 

Register now at https://www.asgct.org/PolicySummit for invaluable insights on navigating the regulatory landscape. 

In This Episode:

Dr. Daniel Stone
Associate Editor-in-Chief of Molecular Therapy Methods & Clinical Development and Senior Staff Scientist, Infectious Disease Sciences, Vaccine and Infectious Disease Division at Fred Hutch Cancer Center

Dr. Mario Mietzsch
Assistant Scientist, Department of Biochemistry and Molecular Biology, University of Florida

Dr. Robert McKenna
Professor and Director of the Center for Structural Biology, Department of Biochemistry and Molecular Biology, University of Florida

'Electric Dreams' by Scott Buckley - released under CC-BY 4.0.
www.scottbuckley.com.au

Dr. Daniel Stone speaks with Drs. Mario Mietzsch and Robert McKenna from the University of Florida to discuss a recent article published in the <a href="https://www.sciencedirect.com/special-issue/10RZ8HRVPL2">Biomanufacturing in Gene and Cell Therapy special issue of Molecular Therapy Methods &amp; Clinical Development</a> by Drs. Mietzsch, McKenna, and colleagues titled <a href="https://www.cell.com/molecular-therapy-family/methods/fulltext/S2329-0501(23)00064-5?_returnURL=https%3A%2F%2Flinkinghub.elsevier.com%2Fretrieve%2Fpii%2FS2329050123000645%3Fshowall%3Dtrue">Production and characterization of an AAV1-VP3-only capsid: An analytical benchmark standard</a>.
If you enjoy today’s conversation, you’ll also enjoy the upcoming ASGCT Policy Summit in Washington, DC, September 23-24. 
This can't-miss event brings together policymakers and gene and cell therapy experts, including FDA leaders Julie Tierney and Dr. Nicole Verdun, to discuss the latest policies impacting this rapidly evolving field. 
Register now at <a href="https://www.asgct.org/policysummit">https://www.asgct.org/PolicySummit</a> for invaluable insights on navigating the regulatory landscape. 
In This Episode:
Dr. Daniel Stone Associate Editor-in-Chief of Molecular Therapy Methods &amp; Clinical Development and Senior Staff Scientist, Infectious Disease Sciences, Vaccine and Infectious Disease Division at Fred Hutch Cancer Center
Dr. Mario Mietzsch Assistant Scientist, Department of Biochemistry and Molecular Biology, University of Florida
Dr. Robert McKenna Professor and Director of the Center for Structural Biology, Department of Biochemistry and Molecular Biology, University of Florida
'Electric Dreams' by Scott Buckley - released under CC-BY 4.0. <a href="https://protect-us.mimecast.com/s/CXOTCL9w1QUXqP0HBBFDP">www.scottbuckley.com.au</a>

The American Society of Gene & Cell Therapy is the premier membership organization for professionals working in cell and gene therapy. On this network, we're sharing exciting stories from our members and the greater scientific community.

The American Society of Gene &amp; Cell Therapy is the premier membership organization for professionals working in cell and gene therapy. On this network, we're sharing exciting stories from our members and the greater scientific community.

Advertisement